No Data
No Data
Craig-Hallum Upgrades Ironwood Pharmaceuticals(IRWD.US) to Buy Rating
Express News | Ironwood Pharmaceuticals: Do Not Plan to Make Some Apraglutide Commercial Launch Planning Investments
Ironwood Pharmaceuticals Backs 2025 Total Ironwood Rev of $260M-$290M >IRWD
Express News | Ironwood Pharmaceuticals Reiterates Full-Year 2025 Linzess U.S. Net Sales Guidance and Raises Adjusted Ebitda Guidance
Catalyst Watch: Spotlight on Tesla, Alphabet Earnings, AACR Drug Data, and Global PMI Reports
Craig-Hallum Downgrades Ironwood Pharmaceuticals(IRWD.US) to Hold Rating, Announces Target Price $1